dapagliflozin / Generic mfg. - LARVOL DELTA

Dapagliflozin Prevents Heart Failure With Preserved Ejection Fraction by Inhibiting the Sodium/Hydrogen Exchanger. (PubMed, JACC Basic Transl Sci) - "Dapa reversed these changes. Dapa prevented cardiac HFpEF by inhibiting cardiomyocyte NHE1 activity and suppressing macrophage activation."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Inflammation • Metabolic Disorders

Response to "Methodological Considerations in Interpreting Renal [18F]FDG-PET After Short-Term Dapagliflozin Treatment". (PubMed, Diabetes Obes Metab) - No abstract available

Journal

Quality of life and treatment continuity during linezolid therapy in drug-resistant tuberculosis and diabetes (ERS 2026) - "Conclusions. In patients with DR-TB and T2DM receiving linezolid, dapagliflozin was associated with improved glycaemic control, fewer neuropathy-related treatment interruptions and preserved quality of life.Further prospective studies are warranted."

HEOR • Diabetes • Diabetic Neuropathy • Infectious Disease • Metabolic Disorders • Neuralgia • Peripheral Neuropathic Pain • Respiratory Diseases • Tuberculosis • Type 2 Diabetes Mellitus

Dapagliflozin and Right Heart Recovery After ASD Device Closure (clinicaltrials.gov) - P=N/A | N=70 | Not yet recruiting | Sponsor: Assiut University

New trial

Initial Changes in eGFR during Treatment with Balcinrenone and Dapagliflozin: An Exploratory Analysis of the MIRO-CKD Trial. (PubMed, Clin J Am Soc Nephrol) - "In adults with CKD, balcinrenone/dapagliflozin induced a modest acute eGFR reduction which was reversible after treatment discontinuation, did not lead to increased rates of adverse events, and was associated with greater SBP and UACR lowering."

Journal • Chronic Kidney Disease • Nephrology • Renal Disease

Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease. (PubMed, Diabetes Obes Metab) - "SGLT2i showed the broadest cardiorenal benefits, while finerenone and semaglutide provided additional protection across selected outcomes. Finerenone increased hyperkalaemia and treatment discontinuation. The efficacy of finerenone-SGLT2i combination therapy requires further investigation."

Journal • Cardiovascular • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

From snapshot to trajectory: A multimodality right-heart monitoring framework across the heart failure spectrum. (PubMed, Am Heart J Plus) - "This narrative review summarizes the physiological and multimodality imaging basis for serial right-heart assessment across HFrEF, HFmrEF, and HFpEF, using SGLT2 inhibition and dapagliflozin as a contemporary mechanistic example rather than the basis for a drug-specific monitoring algorithm...Suggested reassessment windows are illustrative rather than validated and should be individualized. This framework is intended to complement conventional heart failure assessment and support selective advanced imaging or hemodynamic clarification when clinical and right-heart trajectories are discordant."

Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Improving Dapagliflozin Dosing in Heart Failure Through System-Level Quality Improvement. (PubMed, JACC Case Rep) - "System-level workflow redesign improved adherence to guideline-concordant dapagliflozin prescribing and reduced non-evidence-based low-dose use. Similar implementation strategies may improve delivery of guideline-directed medical therapy in heart failure."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders

Durvalumab-associated nephrotic syndrome and organizing pneumonia: a case report. (PubMed, CEN Case Rep) - "Notably, his proteinuria improved following discontinuation of durvalumab and treatment with losartan potassium, dapagliflozin, and finerenone, without a substantial increase in the glucocorticoid dose. The clinical course highlights the heterogeneity of durvalumab-associated nephrotic syndrome."

Journal • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Infectious Disease • Lung Cancer • Nephrology • Non Small Cell Lung Cancer • Oncology • Pneumonia • Renal Disease • Respiratory Diseases • Solid Tumor

Nintedanib-Associated Glomerular Endothelial Injury With Secondary Collapsing Focal Segmental Glomerulosclerosis: Potential Role of Sodium-Glucose Cotransporter 2 Inhibition. (PubMed, Nephrology (Carlton)) - "Subsequent initiation of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin was temporally associated with a gradual and sustained reduction in proteinuria, with partial remission achieved while preserving the estimated glomerular filtration rate. TKIs may induce both endothelial and podocyte injury and therapeutic options beyond drug withdrawal remain limited. In this context, SGLT2 inhibition may represent a potential adjunctive therapeutic strategy in selected cases with underlying chronic kidney disease and warrants further systematic evaluation."

Journal • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Hypertension • Immunology • Interstitial Lung Disease • Metabolic Disorders • Nephrology • Pulmonary Disease • Renal Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis

EUGLYCEMIC KETOACIDOSIS IN A NONDIABETIC PATIENT WITH HEART FAILURE ON DAPAGLIFLOZIN PRECIPITATED BY ACUTE MYOCARDIAL INFARCTION (CHEST 2026) - No abstract available

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders • Myocardial Infarction

DAPAGLIFLOZIN VS METFORMIN IN NON-OBESE PATIENTS WITH ATRIAL FIBRILLATION AND TYPE 2 DIABETES: A PROPENSITY-MATCHED STUDY (CHEST 2026) - No abstract available

Clinical • Atrial Fibrillation • Cardiovascular • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

EUGLYCEMIC KETOACIDOSIS ASSOCIATED WITH DAPAGLIFLOZIN IN THE SETTING OF ACUTE ALCOHOLIC PANCREATITIS (CHEST 2026) - No abstract available

Metabolic Disorders • Pancreatitis

SGLT2 Inhibitors in Cardiovascular-Kidney-Metabolic Syndrome: Drugs Unifying Heart, Kidney, and Metabolism Pharmacotherapy. (PubMed, Am J Cardiovasc Drugs) - "Importantly, SGLT2 inhibitors such as canagliflozin, dapagliflozin, empagliflozin, and sotagliflozin were well tolerated, though caution is advised in volume-depleted patients or those at risk for genitourinary infections. Positive effects, ranging from glycemic control to renoprotective and cardioprotective properties, support SGLT2 inhibitors as first-line therapy in improving clinical outcomes and quality of life in patients affected by this interconnected disease spectrum."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Diabetes • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus • Urology

Antiproteinuric effect of dapagliflozin attenuates tubule-interstitial injury development in subclinical acute kidney injury animal model. (PubMed, Front Pharmacol) - "These results suggest that the protective effect of dapagliflozin on tubule-interstitial injury development in subAKI is associated with the restoration of total protein O-GlcNAcylation balance, thereby contributing to its anti-proteinuric effect. These results indicate that dapagliflozin could be a possible alternative to the treatment of subAKI."

Journal • Preclinical • Acute Kidney Injury • Chronic Kidney Disease • Nephrology • Renal Disease • B2M • KIM1 • OGT

Comparative Efficacy of Pharmacological Agents for Metabolic Dysfunction-Associated Steatohepatitis: An Updated Network Meta-Analysis (ACG 2026) - "Fourteen treatment arms (n=3,417) were included for steatohepatitis resolution and 17 treatment arms (n=4,329) for fibrosis improvement across trials ranging from 24-96 weeks. Tirzepatide 15 mg showed the highest overall efficacy (OR 14.3), while semaglutide 2.4 mg (OR 3.3) and resmetirom 100 mg (OR 4.0) demonstrated significant benefit in Phase 3 trials. Efruxifermin 50 mg ranked highly for steatohepatitis resolution, whereas dapagliflozin 10 mg showed favorable antifibrotic effects (OR 3.3) in recent studies."

Retrospective data • Fibrosis • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis

Dapagliflozin attenuates methotrexate-induced hepatorenal toxicity in rats: insights into oxidative stress, inflammation, autophagy and apoptosis. (PubMed, Mol Cell Biochem) - "Moreover, Dapa modulated beclin1/LC3 dependent autophagy and caspase-3/Bcl-2 mediated apoptosis in hepatic and renal tissues. In conclusion, Dapa showed substantial hepatorenal protection against MTX-induced hepatorenal toxicity, highlighting a new therapeutic strategy in MTX treatment protocols."

IO biomarker • Journal • Preclinical • Immunology • Inflammation • Oncology • BCL2 • BECN1 • CASP3 • NFKB1 • PPARA

Response by Zhao et al to Letter Regarding Article, "Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial". (PubMed, Circulation) - No abstract available

Clinical • Journal • Atrial Fibrillation • Cardiovascular

Letter by Xu et al Regarding Article, "Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial". (PubMed, Circulation) - No abstract available

Clinical • Journal • Atrial Fibrillation • Cardiovascular

Effect of dapagliflozin on electrocardiographic arrhythmic markers in patients with type 2 diabetes mellitus. (PubMed, Br J Clin Pharmacol) - "Three months of dapagliflozin therapy was associated with improvements in multiple ECG-based arrhythmic markers in patients T2DM."

Journal • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • KEAP1

Durable Insulin-free Remission in A-β+ Ketosis-Prone Diabetes With SGLT2 Inhibition: A Case Report With Longitudinal C-Peptide and CGM Data. (PubMed, Clin Med Insights Endocrinol Diabetes) - "However, these findings are hypothesis-generating, and the contribution of dapagliflozin to remission cannot be determined from a single uncontrolled observation. Prospective studies are required before this strategy can be recommended for routine use."

Journal • Diabetes • Metabolic Disorders

Diabetes, Adiposity, and Functional Phenotypes in HFpEF: A Systematic Review of Recent Treatment-Response Evidence. (PubMed, Cureus) - "Heart failure with preserved ejection fraction (HFpEF) is increasingly understood as a heterogeneous syndrome in which cardiometabolic and functional phenotypes may influence treatment response beyond ejection fraction alone...The included studies evaluated tirzepatide, semaglutide, dapagliflozin, and dapagliflozin plus spironolactone across phenotypes including type 2 diabetes, body mass index (BMI), central adiposity, achieved weight loss, epicardial or paracardiac fat, exercise limitation, frailty, and renal-electrolyte profile...These findings suggest the potential value of a phenotype-informed framework for evaluating cardiometabolic treatment response in HFpEF; however, they are insufficient to support phenotype-guided treatment selection because the evidence was derived predominantly from secondary, pooled, or subgroup analyses rather than prospective phenotype-guided trials. Prospective studies are needed to determine whether integrating diabetes status,..."

Journal • Review • Cardiovascular • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Euglycemic ketoacidosis in a nondiabetic patient receiving dapagliflozin for heart failure. (PubMed, JCEM Case Rep) - "This case demonstrates that euglycemic ketoacidosis may occur in nondiabetic patients without typical precipitants. Early recognition and individualized management can prevent unnecessary escalation of care as SGLT2 inhibitor use expands."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders

Dapagliflozin in Lupus Nephritis: Favorable Real-World Outcomes in a Chilean Cohort (ACR Convergence 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

Evaluating safe ketone thresholds to minimise ketosis in young people with Type 1 Diaberes using Dapagliflozin (KETO-TRACK) (ANZCTR) - P=N/A | N=25 | Not yet recruiting | Sponsor: The Kids Research Institute Australia

New trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus